# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2023 Earnings Results

**Report date:** 2023-11-02 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2023

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 3.48%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $11.59 | N/A | +23.38% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed a positive outlook on product performance despite not providing specific guidance. They are focused on innovation and efficiency.

**Key quotes:**

> Management highlighted strong performance in key product lines.

> They noted ongoing investments in research and development.

> There was an emphasis on maintaining operational efficiency.

### Guidance Changes

No forward guidance was provided during this earnings call.

### What It Means

Regeneron's strong EPS performance, exceeding expectations by over 23%, likely contributed to the 3.48% increase in stock price. The company remains focused on its product lines and operational efficiency, which may position it well for future growth. However, the lack of revenue data and guidance leaves some uncertainty for investors.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2023_